Evidence map›Paper›PMID 34385517›Full record

ArticleScientific reports2021

Cystoid maculopathy is a frequent feature of Cohen syndrome-associated retinopathy.

Pierre-Henry Gabrielle, Laurence Faivre, Isabelle Audo, Xavier Zanlonghi, Hélène Dollfus, Alberta A H J Thiadens, Christina Zeitz, Grazia M S Mancini, Yaumara Perdomo, Saddek Mohand-Saïd and 10 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 4 countries.

Pierre-Henry Gabrielle *Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, Dijon, France.
Laurence Faivre *Inserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France.
Isabelle Audo *Sorbonne Université, INSERM, CNRS, Institut de La Vision, 17 rue Moreau, 75012, Paris, France.
Xavier ZanlonghiMaladies Rares, Service d'Ophtalmologie, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes, France.
Hélène DollfusCentre de Référence Pour Les Affections Rares en Génétique Ophtalmologique (CARGO), FSMR SENSGENE, ERN-EYE, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France.
Alberta A H J ThiadensDepartment of Ophthalmology, Erasmus MC, 3015, Rotterdam, The Netherlands.
Christina ZeitzSorbonne Université, INSERM, CNRS, Institut de La Vision, 17 rue Moreau, 75012, Paris, France.
Grazia M S ManciniDepartment of Clinical Genetics, Erasmus MC, 3015, Rotterdam, The Netherlands.
Yaumara PerdomoCentre de Référence Pour Les Affections Rares en Génétique Ophtalmologique (CARGO), FSMR SENSGENE, ERN-EYE, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France.
Saddek Mohand-SaïdSorbonne Université, INSERM, CNRS, Institut de La Vision, 17 rue Moreau, 75012, Paris, France.
Eléonore LizéInserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France.
Vincent LhussiezInserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France.
Emeline F NandrotSorbonne Université, INSERM, CNRS, Institut de La Vision, 17 rue Moreau, 75012, Paris, France.
Niyazi AcarCentre Des Sciences du Goût Et de L'Alimentation, AgroSup Dijon, CNRS, INRA, Université Bourgogne Franche-Comté, 9E Boulevard Jeanne d'Arc, 21000, Dijon, France.
Catherine Creuzot-GarcherDepartment of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, Dijon, France.
José-Alain SahelSorbonne Université, INSERM, CNRS, Institut de La Vision, 17 rue Moreau, 75012, Paris, France.
Muhammad AnsarInstitute of Molecular and Clinical Ophthalmology Basel, 4031, Basel, Switzerland.
Christel Thauvin-RobinetInserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France.
Laurence DuplombInserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France.
Romain Da CostaInserm, UMR1231, Equipe GAD, Université de Bourgogne Franche Comté, Bâtiment B3, 15 Boulevard du Maréchal de Lattre de Tassigny, 21079, Dijon Cedex, France. romain.dacosta@chu-dijon.fr.
Centre Hospitalier Universitaire Dijon Bourgogne · FRErasmus University Rotterdam · NLHôpitaux Universitaires de Strasbourg · FRInserm · FRUniversité de Bourgogne · FRCentre de recherche Translationnelle en Médecine moléculaire · FRCentre hospitalier national d'ophtalmologie des Quinze-Vingts · FRCentre Hospitalier Universitaire de Rennes · FRCentre National de la Recherche Scientifique · FRInstitut de la Vision · FRMaison des Sciences de l’Homme de Dijon · FRSorbonne Université · FRUniversité Bourgogne Franche-Comté · FRUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cohen syndrome (CS) is a rare syndromic form of rod-cone dystrophy. Recent case reports have suggested that cystoid maculopathy (CM) could affect CS patients with an early onset and high prevalence. Our study aims at improving our understanding and management of CM in CS patients through a retrospective case series of ten CS patients with identified pathogenic variants in VPS13B. Longitudinal optical coherence tomography (OCT) imaging was performed and treatment with carbonic anhydrase inhibitors (CAI) was provided to reduce the volume of cystoid spaces. CM affected eight out of ten patients in our cohort. The youngest patient showed a strong progression of macular cysts from the age of 4.5 to 5 years despite oral CAI medication. Other teenage and young adult patients showed stable macular cysts with and without treatment. One patient showed a moderate decrease of cystoid spaces in the absence of treatment at 22 years of age. Through a correlative analysis we found that the volume of cystoid spaces was positively correlated to the thickness of peripheral and macular photoreceptor-related layers. This study suggests that CAI treatments may not suffice to improve CM in CS patients, and that CM may resolve spontaneously during adulthood as photoreceptor dystrophy progresses.

Indexed as

AdolescentAdultChildChild, PreschoolDevelopmental DisabilitiesFemaleFingersHumansIntellectual DisabilityMacular DegenerationMacular EdemaMaleMicrocephalyMuscle HypotoniaMyopiaObesity

Identifiers

PMID34385517
PMCPMC8361024
OpenAlexW3187675913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.